Axovant Gene Therapies Q3 EPS $(0.62) Down From $(0.27) YoY

Axovant Gene Therapies (NASDAQ:AXGT) reported quarterly losses of $(0.62) per share. This is a 129.63 percent decrease over losses of $(0.27) per share from the same period last year.

Benzinga · 02/10/2020 11:09

Axovant Gene Therapies (NASDAQ:AXGT) reported quarterly losses of $(0.62) per share. This is a 129.63 percent decrease over losses of $(0.27) per share from the same period last year.